Intas Pharma

CDSCO panel authorizes Intas pharma to continue CT study on tofacitinib 2% ointment We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To find out more, see our Cookie Policy and Cookie Settings.Ok